Thursday, December 13, 2012
Publication and contact
Boosting antitumor immune
response by blocking glycolysis
A study in mice suggests
blocking glycolysis with a small molecule could help enhance an antitumor
immune response. In a mouse tumor model, a combination of the
chemotherapeutic agent etoposide with a low dose of the
glycolysis inhibitor 2-deoxy-d-glucose
increased an antitumor T cell response and survival and decreased tumor size
compared with either treatment alone. Next steps include testing 2-DG in
combination with other chemotherapeutics.
In 2011, Threshold
Pharmaceuticals Inc. discontinued development of 2-DG,
which was in Phase I testing for solid tumors.
Published online Dec. 13, 2012
Patent pending; available
Bénéteau, M. et al.
Proc. Natl. Acad. Sci. USA; published online Nov. 19, 2012;
Contact: Jean-Ehrland Ricci, Institut National de la Santé
et de la Recherche Médicale (INSERM), Nice, France
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]